A Phase 2 Study of the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease Authors: Colin Church, Maria Molina‐Molina, Miguel Arias‐Guillén, Patrick Muchmore, Ben R Lavon, Jan De Backer, Natalya Makulova, Bipin Mistry, Jia Guo, Jasmanda Wu, Junaideen Fahumy, Ariel Teper, Peng‐Liang Zhao, Kevin C Mange, Gerald O'Brien Published: 2026 ABSTRACT ABSTRACTTreprostinil palmitil (TP) inhalation powder (TPIP), an investigational formulation of the treprostinil prodrug TP, was designed to provide prolonged pulmonary vasodilation with once‐daily administration. In this phase 2 study (NCT05176951), adults with pulmonary hypertension associated with interstitial lung disease (PH‐ILD) were randomized 3:1 to receive TPIP (n = 29) or placebo (n = 10) for 16 weeks. TPIP was up‐titrated from 80 µg to each patient's maximum tolerated dose (≤ 640 µg). Study endpoints were safety and tolerability (primary); pharmacokinetics of TP and treprostinil (secondary); and clinical worsening, change from baseline in 6‐min walk distance (6MWD), and N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) levels (exploratory). Maximum TPIP dose (640 µg) once daily was achieved by 79.3% of patients. TPIP was well tolerated in this study, with a safety profile generally consistent with previously reported route‐specific treatment‐emergent adverse events (TEAEs) of inhaled treprostinil, such as cough and dyspnea. TEAEs occurred in 93.1% and 90.0% of patients on TPIP and placebo, respectively. Most TEAEs were mild or moderate in both groups. In patients on TPIP and placebo, TEAEs leading to treatment discontinuation occurred in 4 (13.8%) and 3 (30.0%) patients, respectively, and serious AEs occurred in 6 (20.7%) and 4 (40.0%) patients, respectively. Following the 640 µg TPIP dose, the treprostinil elimination half‐life was 7.1 h. In TPIP and placebo groups, clinical worsening was observed in 3 (10.3%) and 5 (50.0%) patients, respectively. Trends for improvement were observed in 6MWD and NT‐proBNP with TPIP treatment. These results suggest that TPIP may be a suitable once‐daily treatment for PH‐ILD.Keywords: phase 2, PH‐ILD, pulmonary vasodilators, TPIP Introduction Pulmonary hypertension due to interstitial lung disease (PH‐ILD) is a subset of WHO Group 3 PH (ie, PH associated with lung diseases and/or hypoxia) and is associated with high morbidity and mortality [1, 2, 3]. PH is a common complication in patients with ILD, including those with idiopathic pulmonary fibrosis, chronic hypersensitivity pneumonitis, and nonspecific interstitial pneumonia, and is associated with lower survival, increased need for supplemental oxygen, and poorer functional status compared with ILD alone [4, 5]. Patients with PH‐ILD also have limited treatment options. Although pulmonary vasodilator therapies approved for the treatment of WHO Group 1 PH have been evaluated in PH‐ILD, their use remains controversial due to inconsistent efficacy and safety concerns [6]. Pulmonary vasodilators may worsen ventilation‐perfusion mismatching in patients with PH‐ILD by unselectively vasodilating pulmonary arteries, which could increase blood flow to poorly ventilated areas of the lung [7]. In contrast, inhaled therapies delivered directly to the lung can achieve therapeutic effects at lower doses with fewer side effects compared with systemically delivered pulmonary vasodilators. Inhaled therapies also have the unique advantage of preferentially redirecting blood flow to areas in the lung with preserved ventilation, thus reducing the risk of ventilation‐perfusion mismatching [7]. Treprostinil, a stable analog of prostacyclin, promotes direct vasodilation of pulmonary and systemic arterial vascular beds and inhibits platelet aggregation [8, 9]. Inhaled treprostinil (Tyvaso) was approved by the FDA in 2021 for the treatment of Group 3 PH based on results of the INCREASE trial [10, 11]. Currently available inhaled prostacyclin formulations require frequent daily dosing (at least three per day) to provide prolonged pulmonary vasodilation, as these agents are rapidly eliminated from the lung and have a short systemic half‐life [10, 12, 13, 14, 15]. Furthermore, systemic adverse events (AEs) associated with prostacyclin agent administration, such as headache, nausea, flushing, diarrhea, and jaw pain, as well as route‐specific AEs associated with inhaled prostacyclin agent administration, such as cough and throat irritation, have been reported [15, 16, 17, 18]. Several of these AEs may limit dose escalations to higher, potentially more efficacious doses of these agents. Treprostinil palmitil (TP), a hexadecyl ester prodrug of treprostinil, was designed to provide prolonged pulmonary vasodilation with once‐daily administration [18, 19]. TP is slowly hydrolyzed in the lungs by endogenous esterases to release active treprostinil (Supporting Information S1: Figure S1) (19). TP has been formulated as a nebulized suspension TP inhalation suspension [TPIS]) or as a dry powder (TP inhalation powder [TPIP]) [15, 20]. Preclinical studies in rat and dog models evaluating TPIS showed sustained levels of treprostinil in the plasma and lung compared with inhaled treprostinil, suggesting prolonged target receptor engagement with TP [15]. Furthermore, the relatively lower levels of treprostinil in the plasma with TP compared with inhaled treprostinil suggest reduced systemic exposure to treprostinil with TP, and therefore, TP may be associated with fewer systemic side effects [15]. Pharmacokinetic (PK) analyses in rats showed that the combined concentration of treprostinil plus the treprostinil molar equivalent of TP in the lung was approximately 1000 times greater than the treprostinil concentration in the plasma; this difference was sustained over 24 h [21]. In vivo analyses in rats and dogs showed that local activity of treprostinil within the lung contributed to the long‐acting vasodilatory effects of TP, which was independent from the effects of treprostinil in the plasma [15, 22]. In a phase 1 study evaluating TPIS in healthy human participants, ~11‐fold lower plasma concentration of treprostinil was observed with TP (85 µg) compared with inhaled treprostinil (54 µg) [23]. Furthermore, the PK profile of TP showed sustained levels of treprostinil in the plasma, consistent with findings in preclinical studies [24]. In a phase 1 study of TPIP, single or multiple once‐daily inhalation doses were well tolerated by healthy adults, and treprostinil PK data supported a once‐daily dosing regimen of TPIP [13]. Here, we report results from a phase 2 study that evaluated the safety and tolerability of TPIP in adult patients with PH‐ILD. Methods Study Design This phase 2, randomized, double‐blind, multicenter, placebo‐controlled study (NCT05176951) evaluated the safety and tolerability of TPIP in patients with PH‐ILD over 16 weeks of treatment (Figure 1). At the end of treatment, patients could transition to a separate open‐label extension study. An independent data monitoring committee reviewed the unblinded data 3 months after randomization of the first patient and every 6 months subsequently, to oversee patient safety. This study was conducted in accordance with the ethical principles derived from international guidelines, including the Declaration of Helsinki, CIOMS International Ethical Guidelines, applicable International Council for Harmonisation Good Clinical Practice Guidelines, and applicable laws and regulations. Study design (NCT05176951). Database lock: April 17, 2024. aAdditional dose escalation was permitted at Week 5 based on Investigator assessment for patients who did not achieve the maximum evaluated dose of 640 µg once daily. Abbreviations: EOS, end of study; EOT, end of treatment; HRCT, high‐resolution computed tomography; R, randomization; TPIP, treprostinil palmitil inhalation powder; QD, once daily. Patients and Procedures Eligible patients were adults aged 18–80 years with a confirmed diagnosis of PH‐ILD (including idiopathic interstitial pneumonia, idiopathic pulmonary fibrosis, connective tissue disease [CTD], and sarcoidosis). PH was confirmed by right heart catheterization within 1 year prior to or during the screening phase. Precapillary PH was confirmed by mean pulmonary arterial pressure ≥ 25 mmHg, pulmonary vascular resistance ≥ 3 Wood Units, and pulmonary capillary wedge pressure of ≤ 15 mmHg, according to the previous definition of precapillary PH. Patients should have walked at least 100 m during a 6‐min walk test at screening. Patients receiving anti‐fibrotics (pirfenidone or nintedanib) for their underlying lung disease should have received a stable dose for at least 30 days before screening. Patients with a primary diagnosis of chronic obstructive pulmonary disease (COPD) and patients receiving therapy approved for pulmonary arterial hypertension (PAH) were excluded. A complete list of eligibility criteria is provided in Supporting Information S1: Table S1. All patients provided written informed consent. Patients who met the eligibility criteria were randomized 3:1 to receive TPIP or placebo in a double‐blind manner using interactive response technology (Figure 1). The indicated TPIP dose levels were achieved by using a combination of capsules containing 80 , 160 , or 320 µg of TP or matching placebo. TPIP or placebo was administered by oral inhalation using a capsule‐based dry powder inhaler device (RS01 Model 7; Berry Global, Italy). The 16‐week treatment period included visits at baseline (Day 1) and at Weeks 2, 3, 5, 10, and 16. The first 3 weeks after randomization was the dose‐titration period. The first administered dose of the study drug (TPIP or placebo) was 80 µg once daily. For each patient, the dose was then up‐titrated from 80 µg to the patient's individual maximum tolerated dose, with dose escalation occurring every 2 days at 80 , 160 , and 240 µg dose levels, every 3 days at 320 µg, and every 4 days at 400 µg or higher. The maximum dose evaluated in the study was 640 µg once daily. Additional dose escalation was permitted at Week 5 for patients who did not achieve the maximum dose of 640 µg once daily. Patients received their achieved individual maximum tolerated dose for the remainder of the treatment period. Patients were followed up for 4 weeks after treatment unless they transitioned to the open‐label extension study. Endpoints and Assessments The primary endpoints were safety and tolerability of TPIP versus placebo, measured by the frequency and severity of treatment‐emergent adverse events (TEAEs; defined as any AE that occurs after the first dose and within 30 days of the last dose of study drug), serious AEs (SAEs), and changes in oxygenation status. The secondary endpoint was evaluation of the PK of TP and treprostinil in plasma. Exploratory efficacy endpoints included the change from baseline in trough 6‐min walk distance (6MWD), pulmonary function, clinical worsening (defined as cardiopulmonary‐related hospitalization, lung transplantation, death from any cause, disease‐related decrease in the 6MWD by ≥ 15% from baseline at two consecutive visits that were at least 24 h apart, or the need for additional PH therapy), N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) levels, quality of life (QoL), and change from baseline in Functional Respiratory Imaging (FRI) parameters, as measured by the volumes of pulmonary vessels, < 5 and > 10 mm2 in cross‐sectional area, as a percentage of total pulmonary vascular volume and reflecting pulmonary vascular blood volume distribution [25]. All AEs and SAEs were collected from the time of receiving informed consent through the end of the 4‐week follow‐up period; non‐serious AEs that occurred prior to the first dose of the study drug were reported as medical history and as TEAEs after the first study drug administration. AEs were categorized according to the Medical Dictionary for Regulatory Activities, v27.0. Changes in oxygenation status were measured by continuous pulse oximetry before, during, and after the 6‐min walk test at baseline and at Weeks 5, 10, and 16. Blood samples for PK assessments were collected at baseline and at Weeks 2, 5, 10, and 16. The 6‐min walk test was performed at screening and prior to dosing (trough walk) at Weeks 5, 10, and 16, or at the time of early treatment discontinuation. NT‐proBNP levels were measured prior to dosing at baseline and at Weeks 5, 10, and 16 (or early discontinuation). Changes in pulmonary function were measured using spirometry at baseline and at each subsequent visit, and lung diffusion capacity for carbon monoxide (DLCO) testing at baseline and at Week 16. Clinical worsening events were assessed by the investigator at each visit throughout the treatment period. QoL outcomes were measured prior to dosing using the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) at baseline and at Weeks 5, 10, and 16 (or early discontinuation) [26]. FRI parameters (Supporting Information S1: Table S2; Supporting Information S1: Figure S2) were calculated from high‐resolution computed tomography (HRCT) scans performed at screening and at Week 16. Additional details on assessments are included in Supporting methods. Statistical Analysis Analyses were conducted in the following patient populations: intent‐to‐treat (ITT) analysis set (all randomized patients); safety analysis set (patients who received at least 1 dose of study drug during the treatment period); PK analysis set (patients who received at least 1 dose of TPIP and with at least 1 post‐dose PK concentration data available); CT protocol analysis set (a subset of patients with HRCT scans performed per CT protocol at screening and at Week 16); and full CT analysis set (a subset of patients for whom technically suitable HRCT scans were performed at screening and at Week 16). The sample size for this study was chosen to obtain reasonable evidence of safety and tolerability; it was based on previous early‐phase studies in this patient population, and not on a formal statistical calculation [27, 28]. Due to the small number of total participants and participants per site, data from all trial sites have been pooled. All statistical analyses were performed at the two‐sided 5% level of significance (95% CI if applicable). All p values are considered nominal. All analyses, except for FRI, were performed using SAS v9.4 (SAS Institute, Cary, NC). No adjustments were made for multiplicity, and p values were exploratory in nature. FRI analyses were performed using R (v3.6.3). The primary safety analyses, including analysis of changes in oxygenation status during the treatment period, were performed by descriptive statistics, using the safety analysis set. Changes in oxygenation status from baseline over time were reported in patients with both baseline and post‐baseline assessments. The secondary PK analyses of TP and treprostinil in plasma were conducted using the PK analysis set. In the exploratory efficacy analyses conducted using the ITT analysis set, the changes from baseline in pulmonary function and CAMPHOR score were analyzed using the mixed model for repeated measures (MMRM) method with factors for treatment group, time point, treatment by time interaction, and covariates for baseline values. An unstructured covariance matrix was used to account for the correlation between repeated measurements from the same patient. The treatment effect on change in trough 6MWD at Weeks 5, 10, and 16 was evaluated using the Wilcoxon rank sum test and the Hodges‐Lehmann estimate of median difference (as an estimate of location shift between two treatment groups for the placebo‐controlled treatment effect). Clinical worsening events were analyzed using Fisher's Exact test to compare differences in the proportion of events between treatment groups and using Kaplan‐Meier analysis to measure the time from randomization to first clinical worsening event (patients who did not experience an event were censored at study end date). A sensitivity analysis for clinical worsening was conducted to exclude patients with the ILD subtype, combined pulmonary fibrosis with emphysema (CPFE). The change from baseline in NT‐proBNP levels was analyzed on a log scale by the MMRM method in patients with both baseline and post‐baseline assessments. Changes from baseline in FRI parameters were analyzed in the CT protocol set using an analysis of covariance (ANCOVA) model. The Spearman rank correlation coefficient was calculated to evaluate the relationship between the change from baseline in FRI parameters and clinical parameters (6MWD and NT‐proBNP levels) over 16 weeks in the full CT analysis set. Results Patients and Baseline Characteristics Of 62 patients screened for eligibility (representing 60 unique patients; 2 patients were re‐screened), 39 patients were enrolled at 25 centers across 7 countries between December 22, 2022, and March 14, 2024, and randomized 3:1 to receive either TPIP (n = 29) or placebo (n = 10) (Figure 2). All 39 randomized patients received treatment, and 30 patients completed 16 weeks of treatment. The results of this study were based on a database lock date of April 17, 2024. A full list of study sites and investigators can be found in Supporting Information S1: Table S3. Patient disposition. Of 62 patients screened for eligibility, 39 patients underwent randomization and received at least one dose of TPIP or placebo (included in the ITT and safety analysis sets). aThere were 62 total screens, representing 60 unique patients (2 patients were re‐screened). Abbreviations: AE, adverse events; ITT, intent‐to‐treat; TPIP, treprostinil palmitil inhalation powder. In the ITT analysis set (N = 39), baseline characteristics were generally similar between the two treatment groups; however, a higher proportion of patients were male in the placebo (80.0%) versus TPIP (69.0%) groups (Table 1). Across both treatment groups, the median age of patients was 68.0 years; most patients were White (84.6%), and the most commonly reported ILD subtype was idiopathic interstitial pneumonia (51.3%). The incidence of CPFE and CTD‐associated interstitial fibrosis (CTD‐ILD) was higher in the placebo group versus the TPIP group (CPFE: 20.0% vs 0%; CTD‐ILD: 30.0% vs 3.4%, respectively). Most patients (TPIP, 72.4%; placebo, 60.0%) received treatment for ILD (antifibrotics, systemic corticosteroids, or immunosuppressants) at baseline, with a higher proportion of patients receiving ≥ 2 ILD treatments in the TPIP (37.9%) versus placebo (20.0%) groups. The use of antifibrotics was also higher in the TPIP group versus the placebo group (nintedanib: 41.4% vs 30.0%; pirfenidone: 17.2% vs 10.0%, respectively) (Table 1). Table 1Patient demographics and characteristics (ITT analysis set, N = 39).ParameterTPIP (n = 29)Placebo (n = 10)Overall (N = 39)Age (years)Mean (SD)65.7 (7.65)63.8 (10.55)65.2 (8.38)Median (IQR)68.0 (60.0, 71.0)65.0 (59.0, 72.0)68.0 (60.0, 71.0)Sex, male, n (%)20 (69.0)8 (80.0)28 (71.8)Country, n (%)Argentina3 (10.3)1 (10.0)4 (10.3)Australia1 (3.4)1 (10.0)2 (5.1)Belgium3 (10.3)03 (7.7)Germany5 (17.2)4 (40.0)9 (23.1)Italy5 (17.2)1 (10.0)6 (15.4)Spain9 (31.0)3 (30.0)12 (30.8)United Kingdom3 (10.3)03 (7.7)Race, White, n (%)24 (82.8)9 (90.0)33 (84.6)BMI (kg/m2), mean (SD)26.82 (4.53)26.08 (3.75)26.63 (4.31)Right heart catheterization, mean (SD)mPAP, mmHg34.3 (9.19)33.6 (10.37)34.1 (9.37)PVR, Wood Units5.42 (2.06)6.70 (3.05)5.75 (2.38)Cardiac index2.53 (0.44)2.39 (0.79)2.49 (0.55)Pulmonary function, mean (SD)FVC % predicted57.5 (15.93)64.2 (15.85)—DLCO % predicted35.3 (11.16)34.2 (19.61)—Supplemental O2 use (L/min), mean (SD)3.3 (2.17)2.3 (2.16)—NT‐proBNP concentrations (pg/mL), mean (SD)a 773.25 (1117.44)1748.17 (2759.31)—6MWD (m), mean (SD)282.6 (102.26)312.7 (159.44)—ILD subtypesIIP17 (58.6)3 (30.0)20 (51.3)HSP5 (17.2)1 (10.0)6 (15.4)CPFE02 (20.0)2 (5.1)CTD‐ILD1 (3.4)3 (30.0)4 (10.3)Other6 (20.7)1 (10.0)7 (17.9)ILD treatments, n (%)Antifibrotics17 (58.6)4 (40.0)21 (53.8)Nintedanib12 (41.4)3 (30.0)15 (38.5)Pirfenidone5 (17.2)1 (10.0)6 (15.4)Corticosteroids (systemic use)11 (37.9)4 (40.0)15 (38.5)Prednisolone4 (13.8)2 (20.0)6 (15.4)Prednisone3 (10.3)2 (20.0)5 (12.8)Meprednisone2 (6.9)02 (5.1)Methylprednisolone2 (6.9)02 (5.1)Immunosuppressants5 (17.2)05 (12.8)Azathioprine2 (6.9)02 (5.1)Methotrexate1 (3.4)01 (2.6)Mycophenolate mofetil1 (3.4)01 (2.6)Mycophenolic acid1 (3.4)01 (2.6)Abbreviations: 6MWD, 6‐min walk distance; BMI, body mass index; CPFE, combined pulmonary fibrosis with emphysema; CTD, connective tissue disease; HSP, hypersensitivity pneumonitis; IIP, idiopathic interstitial pneumonia; ILD, interstitial lung disease; IQR, interquartile range; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; TPIP, treprostinil palmitil inhalation powder. a Assessed in 28 patients in the TPIP group and 9 patients in the placebo group with available baseline data. Patient demographics and characteristics (ITT analysis set, N = 39). Abbreviations: 6MWD, 6‐min walk distance; BMI, body mass index; CPFE, combined pulmonary fibrosis with emphysema; CTD, connective tissue disease; HSP, hypersensitivity pneumonitis; IIP, idiopathic interstitial pneumonia; ILD, interstitial lung disease; IQR, interquartile range; NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; TPIP, treprostinil palmitil inhalation powder. Assessed in 28 patients in the TPIP group and 9 patients in the placebo group with available baseline data. Baseline hemodynamic characteristics were generally balanced between treatment groups and representative of the target population of PH‐ILD, and baseline pulmonary function assessments were generally similar across treatment groups (Table 1). At baseline, the mean 6MWD was lower in the TPIP group (282.6 m; standard deviation [SD] 102.3) versus the placebo group (312.7 m; SD 159.4). Exposure and Follow‐Up TPIP exposure was planned for 16 weeks (112 days). The mean (SD) duration of exposure was 101.0 (32.4) days in the TPIP group compared with 94.0 (27.7) days in the placebo group. In the TPIP group, 23 patients (79.3%) achieved the maximum dose of 640 μg once daily; three patients (10.3%) achieved a dose of 480 μg once daily, one patient (3.4%) achieved a dose of 240 μg once daily, and two patients did not complete the dose‐titration period (due to pneumonia leading to treatment interruption > 7 days in one patient and traumatic subdural hematoma resulting in death in the other patient). The TEAEs leading to dose reduction in the TPIP group were vomiting, dizziness, flushing, musculoskeletal chest pain, and chest discomfort. All patients in the placebo group achieved the matching placebo dose corresponding to the maximum TPIP dose of 640 μg once daily. Five (17.2%) patients in the TPIP group and four (40.0%) patients in the placebo group discontinued treatment early. A total of five (17.2%) and two (20.0%) patients in the TPIP and placebo groups, respectively, discontinued the study early. Reasons for early treatment and study discontinuation are provided in Figure 2. Outcomes Primary Endpoints All 39 randomized patients received at least one dose of study drug (i.e., TPIP or placebo) during the treatment period and were included in the safety analysis set. TPIP was generally well tolerated in these patients during the treatment period; no new safety signals were observed (Table 2). At least one TEAE was reported in 93.1% of patients in the TPIP group versus 90.0% in the placebo group. Most TEAEs in the TPIP group were mild (44.8%) or moderate (31.0%) in intensity. The incidence of severe TEAEs was lower with TPIP (17.2%) versus placebo (40.0%). The most common TEAEs (in > 10% of patients) included cough (51.7%), diarrhea (24.1%), and dyspnea (17.2%) in the TPIP group and cough and diarrhea (20.0% each) in the placebo group (Table 2). Although the incidences of cough and productive cough were higher with TPIP (51.7% and 13.8%, respectively) versus placebo (20.0% and 0%, respectively), all events were mild and none of these events in the TPIP group led to treatment discontinuation or dose reduction. Study drug–related TEAEs were reported in 16 (55.2%) patients in the TPIP group versus four (40.0%) patients in the placebo group (Table 2). The most common study drug–related TEAE was cough (37.9%), which was reported in the TPIP group (Table 3). TEAEs leading to treatment discontinuation occurred in 4 (13.8%) patients with TPIP versus 3 (30.0%) with placebo (Table 3). TEAEs leading to dose reduction were reported in 3 (10.3%) patients and 1 (10.0%) patient in the TPIP and placebo groups, respectively. In the TPIP group, the TEAEs leading to dose reduction included vomiting and dizziness in one patient, flushing and musculoskeletal chest pain in the second patient, and chest discomfort in the third patient; in the placebo group, one patient had a dose reduction due to increased liver function test. The incidence of SAEs was lower with TPIP (20.7%) versus placebo (40.0%); no study drug–related SAEs were reported in either treatment group (Table 2). Two deaths were reported in the TPIP group (one due to pulmonary sepsis and one due to traumatic subdural hematoma) and two were reported in the placebo group (one due to cytomegalovirus infection and one due to ILD progression) (Supporting Table S4); all deaths were attributed to underlying disease progression or comorbid conditions, and none of the deaths were considered by the investigators to be related to study treatment. Table 2Overall summary of safety (safety analysis set, N = 39).TPIP (n = 29)Placebo (n = 10)Overall summary of safety, n (%)Patients with TEAEs27 (93.1)9 (90.0)Study drug–related TEAEsa 16 (55.2)4 (40.0)TEAEs leading to dose reduction3 (10.3)1 (10.0)TEAEs leading to treatment discontinuation4 (13.8)3 (30.0)TEAEs leading to study discontinuation5 (17.2)2 (20.0)SAEs6 (20.7)4 (40.0)Study drug–related SAEs00Deathsb, n (%)2 (6.9)2 (20.0)Most common TEAEs,c n (%)Coughd 15 (51.7)2 (20.0)Diarrhea7 (24.1)2 (20.0)Dyspnea5 (17.2)1 (10.0)Productive coughd 4 (13.8)0Dizziness4 (13.8)0Headache3 (10.3)0Flushing3 (10.3)1 (10.0)Back pain3 (10.3)1 (10.0)Nasopharyngitis3 (10.3)1 (10.0)Pneumonia3 (10.3)0SAEs, n (%)Pneumonia2 (6.9)0COVID‐19 pneumonia1 (3.4)0Lower respiratory tract infection1 (3.4)0Pulmonary sepsis1 (3.4)0Urosepsis1 (3.4)0Bronchitis01 (10.0)Cytomegalovirus infection01 (10.0)Subdural hematoma1 (3.4)0Non–small cell lung cancer1 (3.4)0Dyspnea1 (3.4)0Interstitial lung disease01 (10.0)Pulmonary hypertension01 (10.0)Atrial fibrillation01 (10.0)Right ventricular failure01 (10.0) Note: Adverse events were coded using MedDRA version 27.0. Percentages are based on the total number of patients in the safety analysis set. Patients with ≥ 2 AEs were counted once. a Based on Investigator's evaluation. b Death, including any death that occurred on or after the first dose date; all deaths in the study were related to disease progression or comorbid causes, and none were attributed to TPIP. c Data are reported for events occurring in > 10% of patients in either treatment group. d All events of cough were mild, and none led to treatment discontinuation.Abbreviations: AE, adverse event; MedDRA, Medical Dictionary for Regulatory Activities; SAE, serious adverse event; TEAE, treatment‐emergent adverse event; TPIP, treprostinil palmitil inhalation powder. Overall summary of safety (safety analysis set, N = 39). Note: Adverse events were coded using MedDRA version 27.0. Percentages are based on the total number of patients in the safety analysis set. Patients with ≥ 2 AEs were counted once. Based on Investigator's evaluation. Death, including any death that occurred on or after the first dose date; all deaths in the study were related to disease progression or comorbid causes, and none were attributed to TPIP. Data are reported for events occurring in > 10% of patients in either treatment group. All events of cough were mild, and none led to treatment discontinuation. Abbreviations: AE, adverse event; MedDRA, Medical Dictionary for Regulatory Activities; SAE, serious adverse event; TEAE, treatment‐emergent adverse event; TPIP, treprostinil palmitil inhalation powder. Table 3Summary of study drug–related TEAEs and TEAEs leading to treatment discontinuation (safety analysis set, N = 39).AE, n (%)TPIP (n = 29)Placebo (n = 10)Study drug–related TEAEsa 16 (55.2)4 (40.6)Cough11 (37.9)0Flushing3 (10.3)1 (10.0)Productive cough2 (6.9)0Throat irritation2 (6.9)0Diarrhea2 (6.9)1 (10.0)Dizziness2 (6.9)0Hot flush01 (10.0)Increased liver function01 (10.0)TEAEs leading to discontinuation4 (13.8)3 (30.0)Dyspnea1 (3.4)b 0Pulmonary hypertension1 (3.4)1 (10.0)Traumatic subdural hematoma1 (3.4)0Non–small cell lung cancer1 (3.4)0Right ventricular failure01 (10.0)Cytomegalovirus infection01 (10.0) Note: Adverse events were coded using MedDRA version 27.0. aData are reported for events occurring in > 5% of patients in either treatment group bOne patient in the TPIP group experienced a moderate event of dyspnea that was considered related to the study treatment by the Investigator and led to treatment discontinuation. All other TEAEs leading to discontinuation represented progression of the underlying disease or comorbid conditions and were not related to the study drug.Abbreviations: AE, adverse event; MedDRA, Medical Dictionary for Regulatory Activities; TEAE, treatment‐emergent adverse event; TPIP, treprostinil palmitil inhalation powder. Summary of study drug–related TEAEs and TEAEs leading to treatment discontinuation (safety analysis set, N = 39). Note: Adverse events were coded using MedDRA version 27.0. aData are reported for events occurring in > 5% of patients in either treatment group bOne patient in the TPIP group experienced a moderate event of dyspnea that was considered related to the study treatment by the Investigator and led to treatment discontinuation. All other TEAEs leading to discontinuation represented progression of the underlying disease or comorbid conditions and were not related to the study drug. Abbreviations: AE, adverse event; MedDRA, Medical Dictionary for Regulatory Activities; TEAE, treatment‐emergent adverse event; TPIP, treprostinil palmitil inhalation powder. Mean use of supplemental oxygen during the 6‐min walk test at baseline was higher in the TPIP group (3.3 L/min [SD 2.17]) versus the placebo group (2.3 L/min [SD 2.16]) (Table 4A). A higher proportion of patients used supplemental oxygen at baseline in the TPIP group (79.3%) versus the placebo group (60.0%) during the 6‐min walk; supplemental oxygen use continued to remain generally stable compared with baseline at Week 16 in the two groups (83.3% vs 62.5%, respectively). There was no change from baseline in the mean use of supplemental oxygen during the 6‐min walk at Week 16 in the TPIP group (0 L/min [SD 0.91]). Pre‐test saturation of peripheral capillary oxygenation (SpO2) was similar at baseline across treatment groups, with levels remaining stable at Week 16 compared with baseline in both treatment groups. Lowest SpO2, defined as the lowest SpO2 value during or after the 6‐min walk test, was slightly lower at baseline in the TPIP group (mean 76.7% [SD 11.7]) versus the placebo group (mean 80.9% [SD 9.96]) as well as at Week 16 (TPIP: mean 72.3% [SD 15.1] vs placebo: mean 80.8% [SD 7.1]) (Table 4A). There were no meaningful changes in supplemental oxygen use or SpO2 at rest in either treatment group during the study (Table 4B). Table 4Summary of oxygenation and supplemental oxygen use at baseline and Week 16 (ITT analysis set, N = 39).TPIP (n = 29)Placebo (n = 10)Baseline (n = 29)Week 16 (n = 24)Change from baseline (Week 16)Baseline (n = 10)Week 16 (n = 8)Change from baseline (Week 16)A. At 6‐min walk testSupplemental O2 use (L/min), mean (SD)3.3 (2.17)3.3 (2.12)0.0 (0.91)2.3 (2.16)2.4 (2.20)0.6 (2.20)Pre‐test SpO2 (%), mean (SD)94.6 (4.17)94.0 (5.34)−0.3 (5.64)96.1 (2.51)95.6 (2.56)−0.9 (3.04)Lowest SpO2 (%), mean (SD)76.7 (11.71)72.3a (15.09)−4.6 (11.65)80.9 (9.96)80.8 (7.13)−1.3 (7.03)B. At Restb SpO2 (%), mean (SD)94.5 (2.31)94.6 (2.81)c 0.4 (2.63)92.6 (3.53)95.3 (2.60)1.9 (2.17)Supplemental O2 use (L/min), mean (SD)2.0 (1.86)1.98 (1.87)0.1 (0.93)1.7 (1.49)1.9 (2.23)0.1 (1.89) Note: Lowest SpO2 defined as the lowest SpO2 value during or after the 6‐min walk test.Abbreviations: SD, standard deviation; SpO2, saturation of peripheral capillary oxygenation; TPIP, treprostinil palmitil inhalation powder. a n = 22. b Vital signs were assessed as part of safety assessments prior to study drug administration and were not part of the 6‐min walk test. c n = 25. Summary of oxygenation and supplemental oxygen use at baseline and Week 16 (ITT analysis set, N = 39). Note: Lowest SpO2 defined as the lowest SpO2 value during or after the 6‐min walk test. Abbreviations: SD, standard deviation; SpO2, saturation of peripheral capillary oxygenation; TPIP, treprostinil palmitil inhalation powder. n = 22. Vital signs were assessed as part of safety assessments prior to study drug administration and were not part of the 6‐min walk test. n = 25. Results from other safety evaluations, not included in the primary endpoint, showed no clinically meaningful changes from baseline in hematology and clinical chemistry parameters, vital signs, ECG evaluations, and QT corrected by Fridericia's formula intervals in either treatment group during the study. Secondary Endpoints A total of 29 patients, all from the TPIP group, were included in the PK analysis set. After a once‐daily TPIP dose of 80–640 μg, observed TP plasma concentrations ranged from 10 to 52 pg/mL. However, plasma concentrations of TP in most blood samples were below the limit of quantitation (10 pg/mL). Of 303 post‐baseline blood samples from 28 patients collected at Weeks 2, 5, and 10 and at the end of treatment, 257 were below the limit of quantitation. Following once‐daily TPIP dose of 640 μg, the median time (T max) to reach maximum treprostinil plasma concentration was 1.5 h. After T max, plasma concentrations of treprostinil were sustained during distribution and elimination phase (half‐life of 7.1 h). Furthermore, at steady state, the mean minimum treprostinil concentration (Cmin) was 83.5 pg/mL. These results suggested sustained levels of treprostinil in systemic circulation for over 24 h due to slow prolonged release of treprostinil via metabolism of TP in lungs, which supports the once‐daily dosing of TPIP. Based on the treprostinil elimination half‐life (t 1/2 = 7.1 h), there was negligible accumulation of treprostinil after once‐daily dosing of TP (Table 5). Table 5Treprostinil pharmacokinetics after a single dose and once‐daily administration of TPIP (PK analysis set, n = 29).Parameter, mean (CV%)TPIP, 80 μg (single dose) (n = 28)TPIP (once daily)400 μg (n = 1)480 μg (n = 3)640 μg (n = 20)AUCt, pg•h/mLNA2625 (‐)4675 (23.8)7510 (34.9)a Cmax, pg/mL148.1 (93.4)535.0 (‐)1246 (56.9)1594 (67.0) T max, median (minimum, maximum), h2.00 (0.47, 6.00)2.00 (‐)1.03 (0.50, 2.00)1.46 (0.47, 6.00) t 1/2, hNA11.16 (‐)7.28 (39.5)7.10 (32.9)b CL/F, L/hNA152.4 (‐)106.4 (22.5)95.07 (35.3)a Note: On Day 1, PK samples were collected at pre‐dose and at post‐dose up to 6–8 h, and on Week 10, at post‐dose up to 24 h.Abbreviations: AUCt, area under concentration‐time curve from time 0 to 24 h post‐dose; CL/F, apparent total clearance of drug from plasma after extravascular administration; Cmax, maximum plasma concentration; CV%, coefficient of variation expressed as a percentage; NA, not available; t1/2, elimination half‐life; T max, time to maximum (peak) plasma concentration following treatment; TPIP, treprostinil palmitil inhalation powder. a n = 17. b n = 15. Treprostinil pharmacokinetics after a single dose and once‐daily administration of TPIP (PK analysis set, n = 29). Note: On Day 1, PK samples were collected at pre‐dose and at post‐dose up to 6–8 h, and on Week 10, at post‐dose up to 24 h. Abbreviations: AUCt, area under concentration‐time curve from time 0 to 24 h post‐dose; CL/F, apparent total clearance of drug from plasma after extravascular administration; Cmax, maximum plasma concentration; CV%, coefficient of variation expressed as a percentage; NA, not available; t1/2, elimination half‐life; T max, time to maximum (peak) plasma concentration following treatment; TPIP, treprostinil palmitil inhalation powder. n = 17. n = 15. Exploratory Endpoints Changes in exercise capacity over time in the ITT analysis set, as measured by the 6MWD, are summarized in Table 6. At Week 16, patients receiving TPIP showed a placebo‐corrected median change from baseline in 6MWD of 30 m (95% CI: −49.0, 171.0; nominal p = 0.348). Table 6Summary of exercise capacity change from baseline at Weeks 5, 10, and 16 (ITT analysis set, N = 39).Change from baseline in 6MWD (m)TPIP (n = 29)Placebo (n = 10)Week 5Week 10Week 16Week 5Week 10Week 16Mean (SD)−1.8a (59.6)15.8a (63.7)6.3b (72.5)22.8c (64.3)−8.6d (68.6)−8.9d (122.6)Median0.02.0−4.010.0−15.0−24.0Hodges‐Lehmann estimate location shift TPIP QD – placebo−12.029.530.0———95% Confidence interval location shift−55.0, 30.0−22.0, 83.0−49.0, 171.0——— p value0.39800.34040.3484——— Note: Measurements scheduled or taken after discontinuation due to lack of efficacy or death are considered missing and assigned 0 meters for the 6MWD. For missingness due to other reasons, the last observation was carried forward.Abbreviations: 6MWD, 6‐min walk distance; ITT, intent‐to‐treat; QD, once daily; TPIP, treprostinil palmitil inhalation powder. a n = 25. b n = 24. c n = 9. d n = 8. Summary of exercise capacity change from baseline at Weeks 5, 10, and 16 (ITT analysis set, N = 39). Note: Measurements scheduled or taken after discontinuation due to lack of efficacy or death are considered missing and assigned 0 meters for the 6MWD. For missingness due to other reasons, the last observation was carried forward. Abbreviations: 6MWD, 6‐min walk distance; ITT, intent‐to‐treat; QD, once daily; TPIP, treprostinil palmitil inhalation powder. n = 25. n = 24. n = 9. n = 8. No clinically meaningful changes in pulmonary function test parameters from baseline were observed in either treatment group (Supporting Information S1: Table S5). Clinical worsening events occurred in 10.3% of patients receiving TPIP and 50.0% of patients receiving placebo in the ITT analysis set (Fisher Exact Test p = 0.0164) (Supporting Information S1: Figure S3). A time‐to‐event analysis showed a 90% reduction in risk of clinical worsening with TPIP versus placebo (hazard ratio, 0.10; 95% CI: 0.02, 0.56; log‐rank p = 0.001). Results from the sensitivity analysis, which excluded two patients with CPFE in the placebo group, showed an 83% reduction in risk of clinical worsening with TPIP versus placebo (hazard ratio, 0.17; 95% CI: 0.03, 1.00; log‐rank p = 0.026) (Supporting Information S1: Table S6). The least‐squares mean ratio to baseline for NT‐proBNP levels at Weeks 5, 10, and 16 in the ITT analysis set were 0.65, 0.59, and 0.76 for the TPIP group and 1.26, 1.11, and 1.20 for the placebo group (Supporting Information S1: Figure S4). For patients with NT‐proBNP levels at baseline and Week 16, geometric mean (CV%) at baseline and Week 16, respectively, was 242.9 (304.2) and 197.5 (121.8) for the TPIP group (n = 24) and 338.4 (638.2) and 382.6 (493.3) for the placebo group (n = 7). There was a directional decrease in the geometric mean ratio (Week 16/baseline) of NT‐proBNP concentration in the TPIP group (0.81) and a slight increase in the placebo group (1.13); however, results were not nominally significant at Week 16 (nominal p = 0.183). There was no significant between‐group difference in patient‐reported QoL, as assessed by the CAMPHOR questionnaire (Supporting Information S1: Table S7). FRI Analyses The FRI analysis evaluating the effect of TPIP on pulmonary blood vessel volume and lung parenchyma included a subset of 14 patients with HRCT performed per CT protocol at screening and Week 16 (CT protocol analysis set: TPIP n = 9; placebo n = 5). Demographic and baseline characteristics of patients in the CT protocol analysis set are shown in Supporting Information S1: Table S8A. There was a significant increase from baseline in the volume of small arteries (< 5 mm2) as a fraction of total blood volume (BV5A%TBV) and as a fraction of total arterial volume (BV5A%TAV) with TPIP (+8.4% and +8.0%) versus a decrease with placebo (−5.5% and −3.8%); p = 0.02 and p = 0.05, respectively (Supporting Information S1: Table S9). In contrast, the volume of large arteries (> 10 mm2) as a fraction of total blood volume (BV10A%TBV) and total arterial volume (BV10A%TAV) decreased in the TPIP group but increased in the placebo group (Supporting Table S9). There was an increase from baseline in the ratio of small‐to‐large arterial volume (BV5A:BV10A RATIO) with TPIP (+31.4%) versus a decrease with placebo (−10.5%) (Supporting Information S1: Table S9). Examples of 3D reconstructed pulmonary vascular trees color‐coded by vessel cross‐sectional area in representative patients treated with TPIP or placebo at baseline and Week 16 are shown in Supporting Information S1: Figure S5 and Supporting Information S1: Videos S1 and S2. In a correlation analysis investigating the association between changes in FRI and clinical parameters in patients with PH‐ILD, FRI parameters were calculated from HRCT scans performed at screening and at Week 16 in a subset of 28 patients from both treatment groups (full CT analysis set). Demographic and baseline characteristics of patients in the full CT analysis set are summarized in Supporting Information S1: Table S8B. Overall, an increase in FRI markers of small blood vessels correlated with positive shifts in clinical parameters. An increase in the blood volume in small vessels from baseline significantly correlated with improvement in 6MWD (BV5 and BV5%TBV: p < 0.001; BV5A: p = 0.03; BV5A%TAV: p = 0.05) and reduction in NT‐proBNP levels (BV5: p = 0.01; BV5%TBV: p = 0.02) (Supporting Information S1: Table S10). A decrease in the blood volume in large vessels from baseline significantly correlated with improvement in 6MWD (BV10%TBV: p = 0.003; BV10A%TBV: p = 0.03; BV10A%TAV: p = 0.02) and reduction in NT‐proBNP levels (BV10%TBV: p = 0.01). An increase in the small‐to‐large vessel ratio was significantly associated with improvement in 6MWD (p = 0.003) and reduction in NT‐proBNP levels (p = 0.03). Discussion This phase 2 study is the first clinical study to evaluate the safety and tolerability of TPIP in patients with PH‐ILD. This study showed that TPIP was generally well tolerated as a once‐daily treatment in these patients with PH‐ILD. The maximum dose of 640 μg once daily was achieved by most patients (79.3%) receiving TPIP. The incidence of TEAEs was generally similar in both treatment groups. Overall, the TEAEs reported in this study were as expected for the inhaled prostacyclin class of therapies; most were mild or moderate in severity, and no new safety signals were observed [29]. In the current study, the incidence of cough was higher in the TPIP group (51.7%) versus the placebo group (20.0%). Cough is known to be a commonly occurring AE with inhaled treprostinil [11, 30, 31]. Treprostinil‐induced cough is thought to be mediated by the activation of prostanoid IP receptors on jugular C‐fibers in the airways [31, 32, 33]. However, since data suggest that TP does not interact with the prostanoid IP receptor, it is unlikely that TP interacts directly with C‐fibers [21]. TPIP was designed in an attempt to lower the incidence and severity of cough compared with inhaled treprostinil at equivalent doses, based on inhalation of the inactive prodrug and slow release of treprostinil from TP, resulting in lower treprostinil concentrations at the airway sensory nerves [33]. It should be noted that the maximum daily TPIP dose evaluated in this study (640 μg) was equivalent to ~17 breaths (102 μg) four times daily (QID) of inhaled treprostinil, which is higher than the currently approved dosage for an inhaled treprostinil formulation (54–72 μg QID) [10, 21]. Despite this, all cough events with TPIP were mild in severity, and none of them led to treatment discontinuation or dose reduction. Earlier preclinical studies in guinea pigs, which found cough only occurred at a much higher dose with TPIP compared with inhaled treprostinil (~7‐fold higher based on the treprostinil equivalent inhaled dose), support these findings [33]. One of the concerns for the use of systemic pulmonary vasodilators for the treatment of PH‐ILD is a potential risk of worsening hypoxemia through the uncoupling of the ventilation and perfusion in areas of substantial fibrosis [3]. It has been suggested that inhaled therapies could reduce the risk of ventilation‐perfusion mismatching by redirecting blood flow to the best‐ventilated areas of the lung [27, 34]. Findings from the INCREASE study showed no evidence of ventilation‐perfusion mismatching with inhaled treprostinil [11]. Results from the current study also did not reveal any potential safety concerns related to ventilation‐perfusion mismatching with TPIP, consistent with the results from the INCREASE study [11]. In vitro studies have shown that conversion of TP to treprostinil occurs in the lung tissues before entering the systemic circulation [21]. The plasma PK profile of TP supported once‐daily dosing of TPIP based on the projected lung concentration of treprostinil. Compared with inhaled treprostinil, treatment with a once‐daily dose of TPIP at 400 , 480 , or 640 μg resulted in a much longer treprostinil elimination t1/2 (7.1–11.2 h), suggesting extended pulmonary exposure and prolonged conversion of the TP prodrug, and supporting once‐daily administration of TPIP [33, 35]. The prolonged pulmonary exposure of TP leads to the long‐acting vasodilatory effects of treprostinil in the lung. Once‐daily administration of TPIP may provide a more convenient alternative to inhaled treprostinil, which requires frequent administration due to rapid elimination. Dosing frequency is an important factor impacting adherence to PH treatment, particularly prostacyclin agents [36, 37]. Reducing dosage frequency from multiple daily dosing to once daily may also improve patients' adherence to therapy. Of note, nonadherence to treatment, including prostacyclin agents, was associated with worse clinical outcomes in patients with PAH [38]. Results from the exploratory efficacy analyses showed that patients in the TPIP group had directional improvement of 30 m in trough 6MWD from baseline versus placebo. Although this study was not powered to assess the statistical significance of changes in 6MWD, the findings are generally consistent with those from previous studies that demonstrated improvements in exercise capacity with inhaled treprostinil [11, 39]. Clinical worsening events occurred in a lower proportion of patients in the TPIP group versus the placebo group, and time‐to‐event analysis showed a 90% reduction in risk of clinical worsening in the TPIP versus placebo groups in this study. As patients with CPFE were known to have worse outcomes with inhaled treprostinil and there was a higher proportion of patients with CPFE in the placebo (20%) versus TPIP (0%) groups, a sensitivity analysis that excluded patients with CPFE was conducted, which also showed an 83% reduction in risk of clinical worsening [40]. In the INCREASE study, a 39% reduction in risk of clinical worsening was reported [11]. Differences in sample sizes between the two studies may have contributed to the apparent differences in clinical worsening events. Further research is needed to evaluate the effect of TPIP on clinical worsening. There was a directional decrease in the geometric mean ratio of NT‐proBNP concentration from baseline in the TPIP group (0.81) and a slight increase in the placebo group (1.13); results were similar to those reported in previous studies [11, 39]. This study used the novel, non‐invasive FRI technique to evaluate changes in pulmonary vasculature in patients with PH‐ILD. Vascular remodeling and loss of small pulmonary vessels, known as a “pruning” effect, is described in PH, and is detected as a reduction in small vessel volume on HRCT [25, 41, 42]. In this study, FRI results showed that treatment with TPIP in patients with PH‐ILD resulted in blood volume parameter changes that may be clinically interpreted as demonstrating evidence of small vessel vasodilation and improved pulmonary arteriole recruitment, which was also associated with changes in clinical parameters. Further understanding of the relationship between the radiological and histological changes with TPIP treatment is needed to better utilize FRI‐based methods of vascular quantification to evaluate disease progression as well as response to therapy in PH‐ILD. Strengths of this placebo‐controlled study include a blinded study design, which minimized bias. Individualized dose titration during the initial phase addressed variability in tolerability to prostacyclin receptor agonists. This study was limited by a small sample size, especially in the placebo group; thus, the trial was not powered to demonstrate statistical differences between TPIP and placebo for any endpoints. Furthermore, as small sample sizes did not allow for stratification of subgroups, the treatment groups were not balanced by ILD subtypes. Most enrolled patients in this study were from Europe (84.6%), which may limit the generalizability of the results. In conclusion, results from this study showed that TPIP was generally well tolerated in these patients with PH‐ILD over a 16‐week treatment period. Most patients reached the maximum TPIP dose of 640 µg once daily. No new safety concerns were identified with the use of inhaled TPIP. Markers of efficacy were directionally in favor of patients who received TPIP. Patients in the TPIP group showed reduced risk of clinical worsening, reduction in NT‐proBNP concentration, and improvement in 6MWD from baseline. FRI analysis showed that treatment with TPIP resulted in changes suggestive of small vessel vasodilation and improved pulmonary arteriole recruitment. This phase 2 study suggests that TPIP may be a suitable once‐daily inhaled treatment for patients with PH‐ILD, supporting further clinical development. A phase 3 trial is currently ongoing, which will provide further insights. Author Contributions Colin Church, Maria Molina‐Molina, and Miguel Arias‐Guillén made substantial contributions to the conception of the work and collection of the data. Patrick Muchmore, Ben R. Lavon, and Jan De Backer made substantial contributions to the conception of the Functional Respiratory Imaging analysis and collection of the data. Natalya Makulova, Bipin Mistry, Jasmanda Wu, Junaideen Fahumy, Ariel Teper, Kevin C. Mange, and Gerald O'Brien made substantial contributions to the design of the clinical trial and collection of trial data. Peng‐Liang Zhao and Jia Guo significantly contributed to the statistical analysis. All authors significantly contributed to the design of the work and the interpretation of data and substantially contributed to the revision of the manuscript drafts. All authors have approved the submitted version of the manuscript and agreed to be accountable for any part of the work. Ethics Statement The study was carried out in accordance with the ethical principles derived from international guidelines, including the Declaration of Helsinki and the Council for International Organizations of Medical Sciences International Ethical Guidelines, International Council for Harmonisation Good Clinical Practice Guideline, and applicable local regulatory requirements and laws. Before study entry, all patients provided written informed consent in compliance with International Council for Harmonisation E6 (R2) Good Clinical Practice guidelines, which was submitted by the investigator to the institutional review board (IRB) for the study site. Conflicts of Interest C.C. reports steering committee attendance from Insmed Incorporated and is a member of ISHLT PVD network, British Thoracic Society SAG chair. M.M‐M. served as an investigator in this trial and reports grants and fees for scientific advice from Boehringer Ingelheim, Roche, Ferrer, and Janssen. M.A‐G. reports clinical trial participation for Insmed Incorporated. J.F. reports consultancy work for Insmed Incorporated at the time of study. N.M., B.M., J.G., J.W., A.T., P‐L.Z., K.M., and G.O'B. are employees of and shareholders in Insmed Incorporated. P.M. is an employee of Fluidda Incorporated. B.L., and J.DeB. are employees of and shareholders in Fluidda Incorporated. B.L. participated in an advisory role in the clinical trial design and statistical analysis plan of this trial as pertains to Functional Respiratory Imaging. Supporting information Supporting Video 1 Supporting Video 2 Supporting File Acknowledgments We thank all the patients who participated in the study and their family members and caregivers, as well as the investigators, clinical research teams, and support staff at the study sites for providing patient care and their contributions to this study. We thank David Cipolla and Tam Nguyen for their critical review of the draft manuscript. Medical writing support was provided by Vidya Rajagopalan, PhD, of Envision Spark, an Envision Medical Communications agency, and Michael Pucci, PhD, of The Lockwood Group, and funded by Insmed Incorporated. This trial was sponsored by Insmed Incorporated, which funded trial management and performed statistical analyses. Church C, Molina‐Molina M, Arias‐Guillén M, et al., “A Phase 2 Study of the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease,” Pulmonary Circulation 16 (2026): e70322, 10.1002/pul2.70322. Patrick Muchmore, Jasmanda Wu, and Junaideen Fahumy was affiliated to their respective affiliation at the time of study. Data Availability Statement The datasets generated and/or analyzed during the current study are not publicly available due to patient privacy. References Associated Data Supplementary Materials Supporting Video 1 Supporting Video 2 Supporting File Data Availability Statement The datasets generated and/or analyzed during the current study are not publicly available due to patient privacy.